An integrative review of guidelines for anal cancer screening in HIV-infected persons

AIDS Patient Care and STDs

Volumn 28, Issue 7, 2014, Pages 350-357

  Wells, Jessica S ^a   Holstad, Marcia M ^a   Thomas, Tami ^a   Bruner, Deborah Watkins ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANAL COMPLAINT; ANUS CANCER; ANUS PRURITUS; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DIARRHEA; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION;

ANUS NEOPLASMS; EARLY DETECTION OF CANCER; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; MASS SCREENING; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS;

EID: 84903752399     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2013.0358     Document Type: Article

References (54)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality a mong patients with advanced human immunodeficiency virus infection. New Engl J Med 1998;338:853-860. (Pubitemid 28135961)
2. Palefsky JM, Holly EA. Immunosuppression and coinfection with HIV. JNCI Monographs 2003;2003:41-46.
3. Patel P,Hanson D,Sullivan P,et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States 1992-2003. Ann Intern Med 2008, 148, 728-736. (Pubitemid 351717418)
4. Chaturvedi AK, Madeleine MM, Biggar RJ, et al. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009;101:1120-1130.
5. Chin-Hong PV, Palefsky JM. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol Ther 2005;18:67-76. (Pubitemid 40685549)
6. Chin-Hong PV, Husnik M, Cranston R, et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 2009;23:1135-1142.
7. Holly EA, Ralston ML, Darragh TM, et al. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001;93:843-849. (Pubitemid 32586612)
8. Hou JY, Smot kin D, Grossberg R, et al. High prevalence of high grade anal intraepithelial neoplasia in HIV-infected women screened for anal cancer. J Acquir Immune Defic Syndr 2012;60:169-172.
9. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acq Immune Def Syndr Human Retr ovirol 1998;17:314-319.
10. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for anal human Papillomavirus infection in Human Immunodeficiency Virus (HIV)-positive and highrisk HIV -negative women. J Infect Dis 2001;183:383-391. (Pubitemid 32105597)
11. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neopla sia of the vulva, vagina and anus: A meta analysis. Intl J Cancer 2009;124:1626-1636.
12. Videla S, Darwich L, Canadas M-P, et al. Natural history of human papillomavirus infections involving ana l, penile, and oral sites among HIV-positive men. Sex Trans Dis 2013;40:3-10.
13. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirusassociated cancers in patients with Human Immunodeficiency Viru s infection and Acquired Immunodeficiency Syndrome. J Natl Cancer Inst 2000;92:1500-1510.
14. Shiels MS, Pfeiffer RM, Chaturvedi AK, et al. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst 2012;104:1591-1598.
15. Shiels MS, Cole SR, Kirk G, et al. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. JAIDS 2009;52:611-622.
16. Silverberg MJ, Lau B, J ustice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012;54:1026-1034.
17. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: A systematic review and meta-analysis. Lancet Oncol 2012;13:487-500.
18. Darragh TM, Winkler B. Anal cancer and cervical cancer screening: Key differences. Cancer Cytopathol 2011;119: 5-19.
19. Ortoski RA, Kell CS. Anal cancer and screening guidelines for human papillomavirus in men. J Am Osteopath Assoc 2011;111:S35-S43.
20. Chiao EY, Krown SE, Stier EA., et al. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. JAIDS 2005;40:451-455. (Pubitemid 41669180)
21. Palefsky JM. Practising high-resolution anoscopy. Sex Health 2012;9:580-586.
22. Cachay ER, Mathews WC. Human papillomavirus, anal cancer, and screening considerations among HIV-infected individuals. AIDS Rev 2013;15:122-133.
23. Denny LA, Franceschi S, d e Sanjosé́ S, et al. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012;30:F168-F174.
24. Salit IE,Lytwyn A,Raboud J,et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS 2010, 24, 1307-1313.
25. Lanoix J-P Pannier C, Borel A, et al. Assessing urine human papillomavirus polymerase chain reaction testing as a tool for screening anal HPV infection in HIV-positive MSM. AIDS Patient Care STDs 2012;26:208-213.
26. Whittemore R, Knafl K. The integrative review: Updated methodology. J Adv Nursing 2005;52:546-553. (Pubitemid 41686698)
27. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Mortal Morbid Weekly Rep 2009;58:1-207.
28. National Guideline Clearinghouse. Primary care approach to the HIV-infected patient. http://www.guideline.gov/content.aspx-id = 34268 Last accessed September 24, 2013.
29. New York State Department of Health, Primary Care Approach to the HIV-Infected Patient. New York State Department of Health: New York, 2007.
30. Bower M, Collins S, Cottrill C, et al., British HIV Association guidelines for HIV associated malignancies HIV Med 2008;9:336-388.
31. Medical Advisory Secretariat, Anal dysplasia screening: An evidence-based analysis. Ont Health Technol Assess Ser 2007;7:1-43.
32. United States Department of Veterans Affairs. Primary care of veterans with HIV: Anal dysplasia. http://www.hiv.va .gov/pdf/pcm-manual.pdf (Last accessed October 16, 2013
33. Arbyn M, de Sanjosé S, Saraiya M, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Intl J Cancer 2012;131:1969 -1982.
34. Palefsky JM. Anal canc er prevention in HIV-positive men and women. Curr Opin Oncol 2009;21:433.
35. Palefsky J, Berry JM, Jay N. Anal cancer screening. Lancet Oncol 2012;13:e279-e280.
36. Lazenby GB, Unal ER, Andrews AL, et al. A costeffectiveness analysis of anal cancer screening in HIV-positive women. J Lower Genit Tract Dis 2012;16:275-280.
37. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999;281:1822-1829. (Pubitemid 29231133)
38. Alexander K, Dempsey A, Gillison M, et al. The disease burden of HPV. Infect Dis Child 2010;4-10.
39. Centers for Disese Control and Prevention, FDA licensure of quadrivalent huma n papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Weekly Rep (MMWR): 2010;59:630-632.
40. Chaturvedi AK. Beyond c ervical cancer: Burden of other HPV-related cancers among men and women. J Adolesc Health 2010;46:S20-S26.
41. U.S. Food and Drug Administration. FDA: Gardasil approved to prevent anal cancer. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm237941. htm. Last accessed March 19, 2014.
42. Day PM, Kines RC, Thompson CD, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010;8:260-270.
43. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) viruslike particle (VLP) type 16 prop hylactic vaccine. Vaccine 2007;25:4324-4333. (Pubitemid 46635934)
44. Moscicki A-B, Wheeler C, Romanowski B. et al. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously va ccinated adult women. Vaccine 2012;31:234-241.
45. Beachler DC, D'Souza G, Sugar EA, et al. Natural history of anal vs oral HPV infection in HIV-Infected men and women. J Infect Dis 2013;208:330-339.
46. Feola TD, Albert MB, Shahabi K, et al. Prevalence of HPV in HIV-infected women in the designated AIDS center at Upstate Medical University and the potential benefit of vaccination rega rdless of age. J Assoc Nurses AIDS Care 2013;24:176-179.
47. Rositch AF, Gravitt PE, Smith JS. Growing evidence that HPV infection is associated with an increase in HIV acquisition: Exploring the is sue of HPV vaccination. Sex Trans Infect 2013;89:357-357.
48. Schwartz LM, Castle PE, Follansbee S, et al. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men. J Infect Dis 2013;208:1768-1775.
49. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: A cost-effectiveness modelling analysis. Lancet Infect Dis 2010;10:845-852.
50. Centers for Di sese Control and Prevention, Sexually transmitted diseases treatment guidelines. Mortal Morbid Weekly Rep 2010;59:RR-12.
51. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. New Engl J Med 2011;364:401-411.
52. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202:1246-1253.
53. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New Engl J Med 2011;365:1576-1585.
54. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: A nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011;12:862- 870.